Antares Pharma (ATRS) 10-Q7 Aug 142014 Q2 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'ATRS	'
Entity Registrant Name	'ANTARES PHARMA, INC.	'
Entity Central Index Key	'0001016169	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	130,468,648

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$41,017,975	$39,067,236
Short-term investments	15,004,886	24,014,305
Accounts receivable	3,065,166	1,034,492
Inventories	8,334,688	6,461,051
Deferred costs	1,062,054	375,773
Prepaid expenses and other current assets	1,030,785	1,706,678
Total current assets	69,515,554	72,659,535
Equipment, molds, furniture and fixtures, net	8,613,160	6,952,251
Patent rights, net	2,630,112	1,345,177
Goodwill	1,095,355	1,095,355
Long-term investments	'	6,008,169
Other assets	871,444	871,444
Total Assets	82,725,625	88,931,931
Current Liabilities:	'	'
Accounts payable	6,461,140	6,378,712
Accrued expenses and other liabilities	8,419,221	5,453,075
Deferred revenue	7,306,921	4,531,220
Total current liabilities	22,187,282	16,363,007
Deferred revenue - long term	5,102,111	1,855,196
Total liabilities	27,289,393	18,218,203
Stockholders' Equity:	'	'
Preferred Stock: $0.01 par, authorized 3,000,000 shares, none outstanding	'	'
Common Stock: $0.01 par; authorized 200,000,000 shares; 130,300,648 and 128,740,604 issued and outstanding at June 30, 2014 and December 31, 2013, respectively	1,303,006	1,287,406
Additional paid-in capital	245,974,789	243,375,465
Accumulated deficit	-191,188,271	-173,295,941
Accumulated other comprehensive loss	-653,292	-653,202
Total Stockholders' Equity	55,436,232	70,713,728
Total Liabilities and Stockholders' Equity	$82,725,625	$88,931,931

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred Stock, par value	$0.01	$0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.01	$0.01
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	130,300,648	128,740,604
Common Stock, shares outstanding	130,300,648	128,740,604

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue:	'	'	'	'
Product sales	$3,360,003	$4,512,891	$5,165,305	$7,005,367
Development revenue	1,788,401	588,164	3,209,550	1,381,874
Licensing revenue	928,350	68,662	1,856,479	138,007
Royalties	250,031	667,827	1,297,646	1,840,518
Total revenue	6,326,785	5,837,544	11,528,980	10,365,766
Cost of revenue:	'	'	'	'
Cost of product sales	1,846,193	3,182,767	2,863,630	4,610,408
Cost of development revenue	283,887	297,915	443,195	897,417
Total cost of revenue	2,130,080	3,480,682	3,306,825	5,507,825
Gross profit	4,196,705	2,356,862	8,222,155	4,857,941
Operating expenses:	'	'	'	'
Research and development	3,942,948	4,395,528	8,476,574	7,468,213
Sales and marketing	5,013,929	1,158,236	10,524,131	2,039,489
General and administrative	4,330,981	1,933,768	7,120,947	3,884,198
Total operating expenses	13,287,858	7,487,532	26,121,652	13,391,900
Operating loss	-9,091,153	-5,130,670	-17,899,497	-8,533,959
Other income (expense)	-6,572	27,414	7,167	22,255
Net loss	($9,097,725)	($5,103,256)	($17,892,330)	($8,511,704)
Basic and diluted net loss per common share	($0.07)	($0.04)	($0.14)	($0.07)
Basic and diluted weighted average common shares outstanding	130,051,896	126,462,677	129,855,169	126,285,677

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Net loss	($9,097,725)	($5,103,256)	($17,892,330)	($8,511,704)
Foreign currency translation adjustment	-2,281	911	-90	-18,444
Comprehensive loss	($9,100,006)	($5,102,345)	($17,892,420)	($8,530,148)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($17,892,330)	($8,511,704)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	503,786	159,735
Stock-based compensation expense	1,203,596	882,598
Amortization of premiums and discounts	17,587	118,326
Changes in operating assets and liabilities:	'	'
Accounts receivable	-2,030,674	-2,101,486
Inventories	-1,873,637	-27,741
Prepaid expenses and other current assets	675,851	-381,289
Deferred costs	-686,281	-9,409
Other assets	'	-11,844
Accounts payable	-1,083,503	2,316,452
Accrued expenses and other current liabilities	2,003,987	-132,324
Deferred revenue	6,022,693	-1,001,353
Net cash used in operating activities	-13,138,925	-8,700,039
Cash flows from investing activities:	'	'
Purchases of equipment, molds, furniture and fixtures	-918,337	-1,807,732
Additions to patent rights	-252,580	-89,778
Proceeds from maturities of investment securities	15,000,000	3,000,000
Purchases of investment securities	'	-9,118,161
Net cash provided by (used in) investing activities	13,829,083	-8,015,671
Cash flows from financing activities:	'	'
Proceeds from exercise of stock options and warrants	1,415,725	645,655
Taxes paid related to net share settlement of equity awards	-154,397	-104,329
Net cash provided by financing activities	1,261,328	541,326
Effect of exchange rate changes on cash and cash equivalents	-747	-7,708
Net increase (decrease) in cash and cash equivalents	1,950,739	-16,182,092
Cash and cash equivalents:	'	'
Beginning of period	39,067,236	52,097,064
End of period	41,017,975	35,914,972
Noncash investing activities:	'	'
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	1,133,065	'
Additions to patent rights recorded in accounts payable and accrued expenses	$1,145,128	'

Description_of_Business

Description of Business	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Description of Business	'
	1	Description of Business

	Antares Pharma, Inc. (the “Company” or “Antares”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company has numerous partnerships with pharmaceutical companies as well as multiple internal product development programs. The Company has developed both subcutaneous and intramuscular injection technology systems which include Vibex® disposable pressure-assisted auto injectors, reusable needle-free injectors, and disposable multi-use pen injectors.

	On October 14, 2013, the Company announced the approval of OTREXUP™ (methotrexate) injection by the FDA, and in January 2014 announced the launch of OTREXUP™ and in February began detailing the product to health care professionals. OTREXUP™ is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP™ is indicated for adults with severe active rheumatoid arthritis (“RA”) or children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company has worldwide marketing rights for OTREXUP™. The Company commercializes OTREXUP™ in the U.S. for the treatment of RA and has provided LEO Pharma the exclusive right to commercialize OTREXUP™ in the U.S. for the treatment of psoriasis.

	The Company is also developing Vibex® QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency. In February 2014 the Company announced positive top line results from a clinical study evaluating the PK of testosterone enanthate administered weekly by subcutaneous injection at doses of 50 mg and 100 mg via the VIBEX® QS T auto injector device in adult males with testosterone deficiency. The study results were considered positive in that most of the 39 patients enrolled achieved average levels of testosterone within the normal range from the first dose onward. Vibex® QS T was also safe and well tolerated by all dosed patients. On July 22, 2014, the Company announced that the first patient was dosed in a Phase 3 double-blind, multiple-dose study to evaluate the efficacy and safety of QuickShot® Testosterone administered subcutaneously once each week to adult males with testosterone deficiency.

	The Company has licensed its reusable needle-free injection device for use with human growth hormone (“hGH”) to Teva Pharmaceutical Industries, Ltd. (“Teva”), Ferring Pharmaceuticals BV (“Ferring”) and JCR Pharmaceuticals Co., Ltd. (“JCR”), with Teva and Ferring being two of the Company’s primary customers. The Company’s needle-free injection device is marketed by Teva as the Tjet® injector system to administer their 5mg Tev-Tropin® brand hGH marketed in the U.S. The Company’s needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet® 2 Vision and Zomajet® Vision X, respectively, in Europe and Asia. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.

	The Company also has a portfolio of gel-based products. Gelnique 3%™, the Company’s topical oxybutynin gel product for the treatment of overactive bladder (“OAB”), which was approved by the FDA in December 2011, is currently being marketed by Actavis plc in the U.S. The Company has also entered into a licensing agreement with Daewoong Pharmaceuticals under which Daewoong has the rights to commercialize the product in South Korea. The Company’s gel portfolio also includes Elestrin® (estradiol gel) currently marketed by Meda Pharma in the U.S. for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

	The Company has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate head office, Product Development Group and Commercial Group are located in Ewing, New Jersey, where the Product Development Group directs the clinical, regulatory and commercial development of the Company’s internal drug/device combination products. The Commercial Group is responsible for sales, marketing, medical affairs, trade and third party reimbursement for internally developed products.

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies	'
	2	Basis of Presentation and Significant Accounting Policies

	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission’s Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

	Certain prior year amounts have been reclassified in the consolidated financial statements to conform to the current year presentation. These reclassifications were made to present sales and marketing as a separate line item as the Company commences commercialization of OTREXUP™. Business development expenses previously included within sales, marketing and business development have been reclassified to general and administrative expense. These reclassifications had no effect on previously reported net income or total operating expenses.

	Investments

	All short-term and long-term investments are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. The securities are carried at their amortized cost. The fair value of all securities is determined by quoted market prices. At June 30, 2014 the short-term investments had a fair value of $15,012,573 and a carrying value of $15,004,886. At December 31, 2013 the short-term investments had a fair value of $24,021,522 and a carrying value of $24,014,305 and the long-term investments had a fair value of $6,007,851 and a carrying value of $6,008,169.

	Inventories

	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production and assembly operations are outsourced to third-party suppliers where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides reserves for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales. Inventories consist of the following:



			June 30,		December 31,
			2014		2013
	Inventories:
	Raw material		$	883,048	$	1,056,054
	Work in process			4,481,893		3,034,321
	Finished goods			2,969,747		2,370,676

			$	8,334,688	$	6,461,051


	Capitalized Patent Costs

	The Company capitalizes external legal patent defense costs and costs for pursuing patent infringements when it determines that a successful outcome is probable and will lead to an increase in the value of the patent. The capitalized costs will be amortized over the remaining life of the related patent. If changes in the anticipated outcome were to occur that reduce the likelihood of a successful outcome of the entire action to less than probable, the capitalized costs would be charged to expense in the period in which the change is determined. As of June 30, 2014 and December 31, 2013, $1.3 million and $0.1 million of external legal patent costs were capitalized, respectively.



	Product Revenue

	In February 2014, the Company began detailing OTREXUP™ to health care professionals in the United States and began shipping to wholesale pharmaceutical distributors, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. Given the limited sales history of OTREXUP™, the Company currently cannot reliably estimate expected returns of the product at the time of shipment. Accordingly, the Company defers recognition of revenue on product shipments of OTREXUP™ until the right of return no longer exists, which occurs at the earlier of the time OTREXUP™ units are dispensed through patient prescriptions or expiration of the right of return. Units dispensed are generally not subject to return, except in the rare cases where the product malfunctions or the product is damaged in transit. The Company estimates patient prescriptions dispensed using third-party market prescription data. The Company does not have significant history estimating the number of patient prescriptions dispensed. If the Company underestimates or overestimates patient prescriptions dispensed for a given period, adjustments to revenue may be necessary in future periods.

	The Company recognized $1,884,315 in OTREXUP™ product revenue from U.S. customers for the six months ended June 30, 2014, which is net of estimated wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs. The Company had a deferred revenue balance of $1,686,512 at June 30, 2014 for OTREXUP™ product shipments, which is net of estimated wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs.

	The Company will continue to recognize revenue upon the earlier to occur of prescription units dispensed or expiration of the right of return until it can reliably estimate product returns, at which time the Company will record a one-time increase in net revenue related to the recognition of revenue previously deferred. In addition, the costs of manufacturing OTREXUP™ associated with the deferred revenue are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized.

	Product Sales Allowances

	The Company recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company’s agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company’s product sales allowances include:

	Wholesaler Distribution Fees. The Company pays distribution fees to certain wholesale distributors based on contractually determined rates. The Company accrues the fee on shipment to the respective wholesale distributors and recognizes the fee as a reduction of revenue in the same period the related revenue is recognized.

	Prompt Pay Discounts. The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

	Chargebacks. Through June 30, 2014, the Company has been subject to a minimal amount of chargebacks. The Company expects to provide discounts primarily to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company will estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized.

	Rebates. The Company participates in certain rebate programs, which provide discounted prescriptions to qualified insured patients, including Medicare and Medicaid programs. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated future percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized.

	Patient Discount Programs. The Company offers discount card programs to patients for OTREXUP™ in which patients receive discounts on their prescriptions that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on historical redemption experience and on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	3	Stockholders’ Equity

	Stock Options, Stock Awards and Warrants

	The Company records compensation expense associated with share based awards granted to employees at the fair value of the award on the date of grant. The expense is recognized over the period during which an employee is required to provide services in exchange for the award.

	The Company’s 2008 Equity Compensation Plan (the “Plan”) allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. Under the Plan, the maximum number of shares authorized for issuance is 21,000,000 and the maximum number of shares of stock that may be granted to any one participant during a calendar year is 1,000,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is either 10 (for US employees) or 11 (for Swiss employees) years and the options vest in varying periods. As of June 30, 2014, the Plan had 3,517,225 shares available for grant. Stock option exercises are satisfied through the issuance of new shares.

	A summary of stock option activity under the Plan as of June 30, 2014, and the changes during the six months then ended is as follows:



			Number of			Weighted			Weighted		Aggregate
			Shares			Average			Average		Intrinsic
						Exercise			Remaining		Value ($)
						Price ($)			Contractual
									Term
									(Years)
	Outstanding at December 31, 2013			7,697,892			1.89
	Granted			1,957,701			3.08
	Exercised			(699,678	)		1.24					2,283,341
	Cancelled/Forfeited			(102,598	)		3.29

	Outstanding at June 30, 2014			8,853,317			2.19			6.7		6,928,338

	Exercisable at June 30, 2014			5,904,809			1.63			5.3		6,925,243




	Total recognized compensation expense for stock options was approximately $808,000 and $581,000 for the first six months of 2014 and 2013, respectively and was approximately $448,000 and $321,000 for the three month periods ended June 30, 2014 and 2013, respectively. As of June 30, 2014, there was approximately $4,100,000 of total unrecognized compensation cost related to nonvested outstanding stock options that is expected to be recognized over a weighted average period of approximately 2.2 years.

	The per share weighted average fair values of options granted during the first six months of 2014 and 2013 were estimated as $3.08 and $2.24 on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock price. The weighted average expected life is based on both historical and anticipated employee behavior.



			June 30,
			2014			2013
	Risk-free interest rate			1.7	%		0.7	%
	Annualized volatility			62	%		62.5	%
	Weighted average expected life, in years			6			6
	Expected dividend yield			0	%		0	%

	In the first six months of 2014, 699,678 stock options with a weighted average exercise price of $1.24 were exercised which generated proceeds of $870,726 to the Company. In the first six months of 2013, 530,534 stock options with a weighted average exercise price of $0.72 were exercised which generated proceeds of $383,856 to the Company.

	Stock Awards

	At times, the Company makes discretionary grants of its common stock to members of management and other employees in lieu of cash bonus awards or in recognition of special achievements. In the first quarter of 2014 there were 150,000 shares of common stock granted to members of executive management as bonus compensation for achievements in 2013. There were no discretionary grants of common stock in 2013 or in the second quarter of 2014.

	Expense is recognized on a straight line basis over the vesting period and is based on the fair value of the stock on the grant date. The fair value of each stock award is determined based on the number of shares granted and the market price of the Company’s common stock on the date of grant.

	In addition to the shares granted to members of management and employees, at times directors receive a portion of their annual compensation in shares of Company common stock. Expense is recognized on a straight line basis over the one year period that the compensation is earned. Expense recognized in connection with shares granted to directors was $343,000 and $266,000 in the six month period ended June 30, 2014 and 2013, respectively and was $163,000 and $83,000 in the three month periods ended June 30, 2014 and 2013, respectively.

	As of June 30, 2014, a total of 18,172 shares granted to one director were unvested, with approximately $13,000 of associated unrecognized compensation cost that is expected to be recognized over 2 months. The shares were granted in 2013 when the fair value was $4.54 per share.

	Long Term Incentive Program (LTIP)

	The Company’s Board of Directors has approved a long term incentive program for the benefit of the Company’s senior executives. Pursuant to the long term incentive program, the Company’s senior executives have been awarded stock options and performance stock units with targeted values based on values granted by the Company’s peer group. In 2014, the program was modified such that the value of the annual award for each senior executive was delivered 50% in the form of performance stock units, 25% in the form of shares of restricted stock and 25% in the form of stock options. In the prior year, 33% of the value for each senior executive was delivered in the form of stock options, 33% of the value was delivered in the form of performance stock units and 33% was delivered in the form of restricted stock. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in quarterly installments over three years, were otherwise granted on the same standard terms and conditions as other stock options granted pursuant to the Plan and are included in the stock options table above. The restricted stock vests in three equal annual installments. Expense recognized in the first six months of 2014 in connection with the restricted stock was approximately $100,000. The performance stock unit awards made to the senior executives will be vested and convert into actual shares of the Company’s common stock based on the Company’s attainment of certain performance goals over a performance period of three years. In connection with performance stock unit awards for defined performance goals considered probable of achievement, a net expense reduction of $48,000 was recognized in the first six months of 2014. The net expense reduction was primarily the result of the reversal of approximately $100,000 of expense associated with awards previously granted to the Company’s former CEO who resigned in June 2014. The performance stock unit awards and restricted stock granted under the long term incentive program are summarized in the following table:



			Performance Stock Units						Restricted Stock
			Number of			Weighted			Number of		Weighted
Shares			Average Fair			Shares			Average Fair
			Value ($)						Value ($)
Outstanding at December 31, 2013				406,663			3.19			155,724		3.96
Granted				611,527			3.07			214,402		3.09
Vested			(75,000	)		1.66			(51,907	)	3.96
Forfeited/Expired			(75,000	)		1.66			—		—

Outstanding at June 30, 2014			868,190			3.37			318,219		3.37


A portion of the shares that were granted as discretionary shares or under the LTIP program that vested in the first six months of 2014 and 2013 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were 38,768 and 30,153 in 2014 and 2013, respectively, and were based on the value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $154,397 and $104,329 in 2014 and 2013, respectively, and are reflected as a financing activity within the Consolidated Statements of Cash Flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.

Warrants

In the first six months of 2014, the Company received proceeds of $545,000 from the exercise of 545,000 warrants. In the first six months of 2013, the Company received proceeds of $261,799 from the exercise of 234,541 warrants. There were 100 and 545,100 warrants outstanding at June 30, 2014 and December 31, 2013, respectively.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
Net Loss Per Share	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	4	Net Loss Per Share

	Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock. Potentially dilutive stock options and warrants excluded from dilutive loss per share because their effect was anti-dilutive totaled 8,853,417 and 10,840,377 at June 30, 2014 and 2013, respectively. The table below discloses the basic and diluted loss per common share.



			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Net loss		$	(9,097,725	)	$	(5,103,256	)	$	(17,892,330	)	$	(8,511,704	)
	Basic and diluted wtd avg common shares outstanding			130,051,896			126,462,677			129,855,169			126,285,677

	Basic and diluted net loss per common share		$	(0.07	)	$	(0.04	)	$	(0.14	)	$	(0.07	)

Industry_Segment_and_Operation

Industry Segment and Operations by Geographic Areas	6 Months Ended
Industry Segment and Operations by Geographic Areas	Jun. 30, 2014
Segment Reporting [Abstract]	'
Industry Segment and Operations by Geographic Areas	'
	5	Industry Segment and Operations by Geographic Areas
	The Company has one operating segment, drug delivery, which includes the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.
	Revenues by customer location are summarized as follows:


			Three Months Ended				Six Months Ended
			June 30,				June 30,
			2014		2013		2014		2013
	United States of America		$	4,572,808	$	5,145,676	$	8,487,467	$	8,672,963
	Europe			1,744,907		604,268		2,830,003		1,537,907
	Other			9,070		87,600		211,510		154,896

			$	6,326,785	$	5,837,544	$	11,528,980	$	10,365,766

	Revenues by product type:


			Three Months Ended				Six Months Ended
			June 30,				June 30,
			2014		2013		2014		2013
	Injection devices and supplies		$	6,118,212	$	5,346,220	$	10,924,994	$	8,782,720
	Transdermal products			208,573		491,324		603,986		1,583,046
	Significant customers comprising 10% or more of total revenue are as follows:


			Three Months Ended				Six Months Ended
			June 30,				June 30,
			2014		2013		2014		2013
	Teva		$	1,856,526	$	4,736,762	$	4,304,813	$	7,192,028
	Ferring			1,744,912		529,943		2,830,008		1,463,582
	LEO Pharma			857,143		—		1,714,286		—
	Actavis			14,120		224,788		180,747		1,099,116

License_Agreements

License Agreements	6 Months Ended
	Jun. 30, 2014
Revenue Recognition [Abstract]	'
License Agreements	'
	6	License Agreements

	LEO Pharma Promotion and License Agreement

	In November 2013 the Company entered into a promotion and license agreement with LEO Pharma (“LEO”). Under this agreement the Company granted LEO the exclusive right to promote OTREXUP™ to dermatologists for symptomatic control of severe recalcitrant psoriasis in adults in the U.S. LEO is responsible for promotion and marketing activities in dermatology and the Company is responsible for the supply of OTREXUP™ product and samples. The Company received from LEO a non-refundable upfront payment of $5.0 million, a milestone payment of $5.0 million and will receive a milestone payment of $10.0 million upon realizing a defined level of net sales in a calendar year. The Company will pay LEO a percentage of net sales generated in dermatology and will record the payments to LEO as sales and marketing expense.



	The Company identified and evaluated a number of deliverables in the agreement and concluded that none of the deliverables have value on a stand-alone basis. As a result, these deliverables do not qualify for treatment as separate units of accounting. Accordingly, the deliverables have been accounted for as a single unit of accounting and each of the payments will be allocated to these deliverables and will be recognized as revenue over the 35 month estimated life of the agreement. The Company recognized revenue in the three and six month periods ended June 30, 2014 of approximately $857,000 and $1,714,000, respectively, and recorded deferred revenue of $7,714,000 at June 30, 2014 in connection with this agreement.

New_Accounting_Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2014
Accounting Changes And Error Corrections [Abstract]	'
New Accounting Pronouncements	'
	7	New Accounting Pronouncements
	In July 2013, the FASB issued Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The adoption of ASU 2013-11 is expected to reduce diversity in practice by providing guidance on the presentation of unrecognized tax benefits. The provisions of ASU 2013-11 are effective for fiscal years and interim periods beginning after December 15, 2013. The adoption of this update in the first quarter of 2014 did not have a material effect on the Company’s consolidated financial statements.

Legal_Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Legal Proceedings	'
	8	Legal Proceedings

	In the first quarter of 2014 Medac Pharma announced that it submitted an NDA to the FDA for an auto-pen containing methotrexate. On February 28, 2014, Antares filed a complaint against Medac Pharma and Medac GmbH (“Medac GmbH”, together with Medac Pharma, “Medac”), the parent company of Medac Pharma, in the United States District Court for the District of Delaware, alleging infringement of two of the Company’s patents for technology regarding an auto-injector and an auto-injector containing methotrexate. The complaint asserts that Medac Pharma’s NDA submission infringes, that Medac Pharma’s proposed product will infringe the Company’s patents, and that Medac Pharma should be enjoined from marketing its product. On March 14, 2014, Antares filed a motion for preliminary injunction seeking to enjoin Medac from selling its methotrexate auto-pen product if and when such product is approved for sale in the United States, pending the final resolution of the litigation. On April 18, an amended complaint was filed asserting four Antares patents, and the motion for preliminary injunction was updated. On July 10, 2014, the District Court denied Antares’ motion for preliminary injunction. The litigation is expected to proceed to a jury trial unless settled by the parties; a trial date has not been set. Antares has filed an appeal of the denial of the motion for preliminary injunction with the U.S. Court of Appeals for the Federal Circuit. During the six months ended June 30, 2014, a total of approximately $1,300,000 in legal costs in connection with this suit has been capitalized. However, there is no assurance of success with any patent litigation, and it could be costly and time consuming and depending on the ultimate outcome of the litigation may have an adverse effect on results of operations and OTREXUP™ market penetration. If the Company determines that the likelihood of a successful outcome of the entire action changes and becomes less than probable, the capitalized costs would be charged to expense in the period in which the change is determined.

	On March 7, 2014, Medac filed suit against Antares, LEO Pharma and its parent company LEO Pharma A/S (together, the “LEO Entities”) in the United States District Court for the District of New Jersey, alleging that Antares and the LEO Entities infringe Medac’s U.S. Patent 8,664,231 (the “231 patent”) that was issued by the U.S. Patent and Trademark Office on March 4, 2014. The complaint states that the 231 patent relates to a concentration of more than 30mg/mL. Medac alleges that OTREXUP™ infringes the 231 patent, and demands that Antares and the LEO Entities be enjoined from making, using, selling, importing or offering OTREXUP™ and pay unspecified amounts of compensatory damages, treble damages and attorneys’ fees. The Company intends to defend itself vigorously. Under the terms of the promotion and license agreement between the Company and the LEO Entities, the Company agreed to indemnify the LEO Entities from claims that OTREXUP™ infringes the intellectual property rights of any third party. On July 1, 2014, Antares filed a petition with the Patent Trial and Appeal Board (the “PTAB”) of the U.S. Patent and Trademark Office seeking an inter partes review of the 231 patent. The PTAB must decide whether to institute review by January 2, 2015. Legal costs in connection with this suit and the inter partes review are expensed as incurred.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Investments	'

	Investments

	All short-term and long-term investments are U.S. Treasury bills or U.S. Treasury notes that are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. The securities are carried at their amortized cost. The fair value of all securities is determined by quoted market prices. At June 30, 2014 the short-term investments had a fair value of $15,012,573 and a carrying value of $15,004,886. At December 31, 2013 the short-term investments had a fair value of $24,021,522 and a carrying value of $24,014,305 and the long-term investments had a fair value of $6,007,851 and a carrying value of $6,008,169.
Inventories	'

	Inventories

	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production and assembly operations are outsourced to third-party suppliers where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides reserves for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales. Inventories consist of the following:



		June 30,		December 31,
		2014		2013
	Inventories:
	Raw material	$	883,048	$	1,056,054
	Work in process		4,481,893		3,034,321
	Finished goods		2,969,747		2,370,676

		$	8,334,688	$	6,461,051

Capitalized Patent Costs	'
	Capitalized Patent Costs
	The Company capitalizes external legal patent defense costs and costs for pursuing patent infringements when it determines that a successful outcome is probable and will lead to an increase in the value of the patent. The capitalized costs will be amortized over the remaining life of the related patent. If changes in the anticipated outcome were to occur that reduce the likelihood of a successful outcome of the entire action to less than probable, the capitalized costs would be charged to expense in the period in which the change is determined. As of June 30, 2014 and December 31, 2013, $1.3 million and $0.1 million of external legal patent costs were capitalized, respectively.
Product Revenue	'
	Product Revenue
	In February 2014, the Company began detailing OTREXUP™ to health care professionals in the United States and began shipping to wholesale pharmaceutical distributors, subject to rights of return within a period beginning six months prior to, and ending 12 months following, product expiration. Given the limited sales history of OTREXUP™, the Company currently cannot reliably estimate expected returns of the product at the time of shipment. Accordingly, the Company defers recognition of revenue on product shipments of OTREXUP™ until the right of return no longer exists, which occurs at the earlier of the time OTREXUP™ units are dispensed through patient prescriptions or expiration of the right of return. Units dispensed are generally not subject to return, except in the rare cases where the product malfunctions or the product is damaged in transit. The Company estimates patient prescriptions dispensed using third-party market prescription data. The Company does not have significant history estimating the number of patient prescriptions dispensed. If the Company underestimates or overestimates patient prescriptions dispensed for a given period, adjustments to revenue may be necessary in future periods.
	The Company recognized $1,884,315 in OTREXUP™ product revenue from U.S. customers for the six months ended June 30, 2014, which is net of estimated wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs. The Company had a deferred revenue balance of $1,686,512 at June 30, 2014 for OTREXUP™ product shipments, which is net of estimated wholesaler discounts, prompt pay discounts, chargebacks, rebates and patient discount programs.
	The Company will continue to recognize revenue upon the earlier to occur of prescription units dispensed or expiration of the right of return until it can reliably estimate product returns, at which time the Company will record a one-time increase in net revenue related to the recognition of revenue previously deferred. In addition, the costs of manufacturing OTREXUP™ associated with the deferred revenue are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized.
Product Sales Allowances	'

	Product Sales Allowances

	The Company recognizes product sales allowances as a reduction of product sales in the same period the related revenue is recognized. Product sales allowances are based on amounts owed or to be claimed on the related sales. These estimates take into consideration the terms of the Company’s agreements with customers and third-party payors and the levels of inventory within the distribution channels that may result in future rebates or discounts taken. In certain cases, such as patient support programs, the Company recognizes the cost of patient discounts as a reduction of revenue based on estimated utilization. If actual future results vary, the Company may need to adjust these estimates, which could have an effect on product revenue in the period of adjustment. The Company’s product sales allowances include:

	Wholesaler Distribution Fees. The Company pays distribution fees to certain wholesale distributors based on contractually determined rates. The Company accrues the fee on shipment to the respective wholesale distributors and recognizes the fee as a reduction of revenue in the same period the related revenue is recognized.

	Prompt Pay Discounts. The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.

	Chargebacks. Through June 30, 2014, the Company has been subject to a minimal amount of chargebacks. The Company expects to provide discounts primarily to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company will estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized.

	Rebates. The Company participates in certain rebate programs, which provide discounted prescriptions to qualified insured patients, including Medicare and Medicaid programs. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated future percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized.

	Patient Discount Programs. The Company offers discount card programs to patients for OTREXUP™ in which patients receive discounts on their prescriptions that are reimbursed by the Company. The Company estimates the total amount that will be redeemed based on historical redemption experience and on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized.
New Accounting Pronouncements	'
	In July 2013, the FASB issued Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends accounting guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or tax credit carryforward exists. This new guidance requires entities, if certain criteria are met, to present an unrecognized tax benefit, or portion of an unrecognized tax benefit, in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The adoption of ASU 2013-11 is expected to reduce diversity in practice by providing guidance on the presentation of unrecognized tax benefits. The provisions of ASU 2013-11 are effective for fiscal years and interim periods beginning after December 15, 2013. The adoption of this update in the first quarter of 2014 did not have a material effect on the Company’s consolidated financial statements.

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Inventories	'

	Inventories consist of the following:



		June 30,		December 31,
		2014		2013
	Inventories:
	Raw material	$	883,048	$	1,056,054
	Work in process		4,481,893		3,034,321
	Finished goods		2,969,747		2,370,676

		$	8,334,688	$	6,461,051

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
Stockholders' Equity (Tables)	Jun. 30, 2014
Equity [Abstract]	'
Summary of Stock Option Activity	'

	A summary of stock option activity under the Plan as of June 30, 2014, and the changes during the six months then ended is as follows:



		Number of			Weighted			Weighted			Aggregate
		Shares			Average			Average			Intrinsic
					Exercise			Remaining			Value ($)
					Price ($)			Contractual
								Term
								(Years)
	Outstanding at December 31, 2013		7,697,892			1.89
	Granted		1,957,701			3.08
	Exercised		(699,678	)		1.24						2,283,341
	Cancelled/Forfeited		(102,598	)		3.29

	Outstanding at June 30, 2014		8,853,317			2.19			6.7			6,928,338

	Exercisable at June 30, 2014		5,904,809			1.63			5.3			6,925,243



Assumptions Used in Fair Value Measurement of Options Granted	'

		June 30,
		2014			2013
	Risk-free interest rate		1.7	%		0.7	%
	Annualized volatility		62	%		62.5	%
	Weighted average expected life, in years		6			6
	Expected dividend yield		0	%		0	%
Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program	'

	The performance stock unit awards and restricted stock granted under the long term incentive program are summarized in the following table:



		Performance Stock Units						Restricted Stock
		Number of			Weighted			Number of			Weighted
		Shares			Average Fair			Shares			Average Fair
					Value ($)						Value ($)
	Outstanding at December 31, 2013		406,663			3.19			155,724			3.96
	Granted		611,527			3.07			214,402			3.09
	Vested		(75,000	)		1.66			(51,907	)		3.96
	Forfeited/Expired		(75,000	)		1.66			—			—

	Outstanding at June 30, 2014		868,190			3.37			318,219			3.37

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
Net Loss Per Share (Tables)	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Basic and Diluted Loss Per Common Share	'

	The table below discloses the basic and diluted loss per common share.



		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Net loss	$	(9,097,725	)	$	(5,103,256	)	$	(17,892,330	)	$	(8,511,704	)
	Basic and diluted wtd avg common shares outstanding		130,051,896			126,462,677			129,855,169			126,285,677

	Basic and diluted net loss per common share	$	(0.07	)	$	(0.04	)	$	(0.14	)	$	(0.07	)

Industry_Segment_and_Operation1

Industry Segment and Operations by Geographic Areas (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Summary of Revenues by Customer Location	'
	Revenues by customer location are summarized as follows:


		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	United States of America	$	4,572,808	$	5,145,676	$	8,487,467	$	8,672,963
	Europe		1,744,907		604,268		2,830,003		1,537,907
	Other		9,070		87,600		211,510		154,896

		$	6,326,785	$	5,837,544	$	11,528,980	$	10,365,766

Summary of Revenues by Product Type	'
	Revenues by product type:


		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Injection devices and supplies	$	6,118,212	$	5,346,220	$	10,924,994	$	8,782,720
	Transdermal products		208,573		491,324		603,986		1,583,046
Summary of Significant Customers Comprising 10% or More of Total Revenue	'
	Significant customers comprising 10% or more of total revenue are as follows:


		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Teva	$	1,856,526	$	4,736,762	$	4,304,813	$	7,192,028
	Ferring		1,744,912		529,943		2,830,008		1,463,582
	LEO Pharma		857,143		—		1,714,286		—
	Actavis		14,120		224,788		180,747		1,099,116

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Facility
	Customer
	Patient
Description Of Business [Abstract]	'
Number of patients enrolled in the study	39
Number of primary customers	2
Number of facility locations	2

Basis_of_Presentation_and_Sign3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
	Jun. 30, 2014	Dec. 31, 2013	United States of America [Member]
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Short term investments, fair value	$15,012,573	$24,021,522	'
Short term investments, carrying value	15,004,886	24,014,305	'
Long-term investments, fair value	'	6,007,851	'
Long-term investments, carrying value	'	6,008,169	'
Capitalized legal patent cost	1,300,000	100,000	'
Product revenue	'	'	1,884,315
Deferred revenue balance	'	'	$1,686,512
Cash discount to incentive for prompt payment	'	'	2.00%

Basis_of_Presentation_and_Sign4

Basis of Presentation and Significant Accounting Policies - Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Inventories	'	'
Raw material	$883,048	$1,056,054
Work in process	4,481,893	3,034,321
Finished goods	2,969,747	2,370,676
Inventory, Total	$8,334,688	$6,461,051

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Long Term Incentive Program [Member]

Warrant [Member]

Directors [Member]

Stock Options [Member]

Discretionary Shares [Member]

Restricted Stock [Member]

Performance Stock Units [Member]

Former Chief Executive Officer [Member]

United States of America [Member]

Switzerland [Member]

Stock Option [Member]

Long Term Incentive Program [Member]

Employees [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation arrangement by share-based payment award, number of shares authorized

21,000,000

Maximum number of shares of stock granted to one participant

1,000,000

Minimum percentage of exercise price

100.00%

Contractual term of options granted

'10 years

'11 years

Shares available for grant under the plan

3,517,225

Recognized stock-based compensation expense

$163,000

$83,000

$343,000

$266,000

$448,000

$321,000

$808,000

$581,000

$100,000

Unrecognized compensation cost related to nonvested outstanding stock awards

13,000

4,100,000

Weighted average period expected to be recognized

'2 months

'2 years 2 months 12 days

Per share weighted average fair values of options granted

$3.08

$2.24

Number of stock options exercised

699,678

530,534

Weighted average exercise price of stock options

$1.24

$0.72

Proceeds from the issuance of stock options

870,726

383,856

Share based payment discretionary awards shares granted

150,000

Stock grants unvested

18,172

318,219

155,724

868,190

406,663

Fair value of shares granted

$4.54

$3.96

$1.66

Options granted under long term incentive program vesting period

'3 years

Share based compensation award percentage

25.00%

33.00%

25.00%

33.00%

50.00%

33.00%

Performance stock unit awards expenses

48,000

100,000

Shares withheld to meet employees' minimum statutory income tax obligation

38,768

30,153

Payments for the employees' minimum statutory income tax obligation

154,397

104,329

Proceeds from warrant exercised

$545,000

$261,799

Warrants exercised

545,000

234,541

Warrants outstanding

100

545,100

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Stockholders Equity Note [Abstract]	'	'
Number of Shares Outstanding, Beginning	7,697,892	'
Number of Shares Granted	1,957,701	'
Number of Shares Exercised	-699,678	-530,534
Number of Shares canceled/Forfeited	-102,598	'
Number of Shares Outstanding, Ending	8,853,317	'
Number of Shares Exercisable, Ending	5,904,809	'
Weighted Average Exercise Price Outstanding, Beginning Balance	$1.89	'
Weighted Average Exercise Price Granted	$3.08	'
Weighted Average Exercise Price Exercised	$1.24	$0.72
Weighted Average Exercise Price Cancelled/Forfeited	$3.29	'
Weighted Average Exercise Price Outstanding, Ending Balance	$2.19	'
Weighted Average Exercise Price Exercisable, Ending Balance	$1.63	'
Weighted Average Remaining Contractual Term Outstanding, Ending	'6 years 8 months 12 days	'
Weighted Average Remaining Contractual Term Exercisable, Ending	'5 years 3 months 18 days	'
Aggregate Intrinsic Value, Exercised	$2,283,341	'
Aggregate Intrinsic Value Outstanding, Ending	6,928,338	'
Aggregate Intrinsic Value Exercisable, Ending	$6,925,243	'

Stockholders_Equity_Assumption

Stockholders' Equity - Assumptions Used in Fair Value Measurement of Options Granted (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Stockholders Equity Note [Abstract]	'	'
Risk-free interest rate	1.70%	0.70%
Annualized volatility	62.00%	62.50%
Weighted average expected life, in years	'6 years	'6 years
Expected dividend yield	0.00%	0.00%

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long Term Incentive Program (Detail) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
	Jun. 30, 2013	Performance Stock Units [Member]	Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Shares, Beginning Balance	'	406,663	155,724
Number of Shares, Granted	'	611,527	214,402
Number of Shares, Vested	'	-75,000	-51,907
Number of Shares, Forfeited/Expired	'	-75,000	'
Number of Shares, Ending Balance	'	868,190	318,219
Weighted Average Fair Value, Beginning Balance	'	$3.19	$3.96
Weighted Average Fair Value, Granted	'	$3.07	$3.09
Weighted Average Fair Value, Vested	$4.54	$1.66	$3.96
Weighted Average Fair Value, Forfeited/Expired	'	$1.66	'
Weighted Average Fair Value, Ending Balance	'	$3.37	$3.37

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail)	3 Months Ended	6 Months Ended
Net Loss Per Share - Additional Information (Detail)	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'
Dilutive stock options and warrants excluded from dilutive loss per share	8,853,417	10,840,377

Net_Loss_Per_Share_Basic_and_D

Net Loss Per Share - Basic and Diluted Loss Per Common Share (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net loss	($9,097,725)	($5,103,256)	($17,892,330)	($8,511,704)
Basic and diluted weighted average common shares outstanding	130,051,896	126,462,677	129,855,169	126,285,677
Basic and diluted net loss per common share	($0.07)	($0.04)	($0.14)	($0.07)

Industry_Segment_and_Operation2

Industry Segment and Operations by Geographic Areas - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Segment
Segment Reporting Information [Line Items]	'
Number of operating segment	1
Sales [Member]	'
Segment Reporting Information [Line Items]	'
Total revenue	10.00%

Industry_Segment_and_Operation3

Industry Segment and Operations by Geographic Areas - Revenues By Customer Location (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	$6,326,785	$5,837,544	$11,528,980	$10,365,766
United States of America [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	4,572,808	5,145,676	8,487,467	8,672,963
Europe [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	1,744,907	604,268	2,830,003	1,537,907
Other [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	$9,070	$87,600	$211,510	$154,896

Industry_Segment_and_Operation4

Industry Segment and Operations by Geographic Areas - Revenues By Product Type (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	$6,326,785	$5,837,544	$11,528,980	$10,365,766
Injection devices and supplies [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	6,118,212	5,346,220	10,924,994	8,782,720
Transdermal products [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	$208,573	$491,324	$603,986	$1,583,046

Industry_Segment_and_Operation5

Industry Segment and Operations by Geographic Areas - Summary of Significant Customers Comprising 10% or More of Total Revenue (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	$6,326,785	$5,837,544	$11,528,980	$10,365,766
Teva [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	1,856,526	4,736,762	4,304,813	7,192,028
Ferring [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	1,744,912	529,943	2,830,008	1,463,582
LEO Pharma [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	857,143	'	1,714,286	'
Actavis [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total revenues	$14,120	$224,788	$180,747	$1,099,116

License_Agreements_Additional_

License Agreements - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended
	Nov. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
Deferred Revenue Arrangement [Line Items]	'	'	'
Non refundable upfront payment	$5,000,000	'	'
Revenue recognized	'	857,000	1,714,000
Recognition of deferred revenue	'	'	7,714,000
Revenue recognition period of deliverables	'	'	'35 months
Performance obligations [Member]	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'
Milestone payment received	'	'	5,000,000
Realizing a defined level of net sales [Member]	'	'	'
Deferred Revenue Arrangement [Line Items]	'	'	'
Milestone payment receivable	$10,000,000	'	'

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)	6 Months Ended
Legal Proceedings - Additional Information (Detail) (USD $)	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Legal costs capitalized as patent costs	$1,300,000